Abstract:Abstract Glioblastoma multiform (GMB), as a major unsolved clinical challenge, remains among the most aggressive malignancies in human brain with poor prognosis around 10-14.6 months survival. Due to their infiltrative character in the limited space, it is very difficult to be completely resected surgically. Although radiotherapy and chemotherapy that were given to patients after surgery may improve overall survival, the treatment outcomes in general are poor. The tumors eventually recur. Thus, new therapeutic strategy for GBM is urgently needed. It has been shown that CD47, a tumor cell surface marker, through binding its receptor SIRPα on macrophages plays as “don't eat me signal” and thus, by blocking the interaction of CD47 with SIRPα could lead to tumor destruction. So, we developed a standardized protocol for a novel xenograft surgical resection model which mimicked the process of operation in clinic. We hypothesized that the mechanical surgical procedure of tumor resection may create an inflammatory tumor environment, leading to recruitment of immune cells including macrophages. We believed the presence of these macrophages was needed to mediate the anti-tumor effects of the CD47 antibody which we administered postoperatively. The aims of the project are: 1) Translating brain tumour immunotherapy from the lab bench via preclinical studies to the clinic; 2) Establishing a novel xenograft surgical resection model to mimic the clinical setting of tumour recurrence in patients. Specifically, we will: 1) In vitro quantify and functionally characterize tumour-associated macrophages from treated vs. untreated tumours; 2) Using our clinical relevant animal models we want to determine the efficacy of targeting CD47 therapy. In this study, we have developed a standardized protocol for a novel xenograft surgical resection model to parallel the treatment seen in glioma patients. The model accounts for the therapeutic benefit of surgical resection in pre-clinical models and demonstrates that recurrent tumors show higher proliferation and angiogenesis comparing to non-resected tumors. Moreover, the resection site is highly infiltrated by both CD68 and pSTAT1 positive macrophages. CD47 antibody treatment group has longer survival time than other groups. Citation Format: Huaiyang Zhu, Ning Yang, Lina Leiss, Cecilie B Rygh, Siddhartha S Mitra, Samuel H Cheshier, Bin Huang, Rolf Bjerkvig, Per Ø Enger, Irving L Weissman, Xingang Li, Jian Wang. Targeting CD47 triggers macrophage-dependent brain tumor destruction in a clinical relevant model. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 1331. doi:10.1158/1538-7445.AM2015-1331

CD47 Promotes the Proliferation and Migration of Adamantinomatous Craniopharyngioma Cells by Activating the MAPK/ERK Pathway, and CD47 Blockade Facilitates Microglia-Mediated Phagocytosis.

CD47 Blockade Inhibits Tumor Progression Human Osteosarcoma in Xenograft Models

CD47 Masks Pro-Phagocytic Ligands in Cis on Tumor Cells to Suppress Antitumor Immunity

Abstract 4866: CD47 Promotes Metastasis and Proliferation of Colorectal Cancer Via MAPK/ERK Pathway

Progress in cancer research on the regulator of phagocytosis CD47, which determines the fate of tumor cells (Review)

Cd47 Promotes Metastasis And Proliferation Of Colorectal Cancer Via Mapk/Erk Pathway

Facilitating cholangiocarcinoma inhibition by targeting CD47

Abstract 1374: Targeting CD47/SIRPɑ axis in urologic cancer triggers enhanced phagocytosis of tumor cell and induces tumor growth inhibition

Immune inactivation by CD47 expression predicts clinical outcomes and therapeutic responses in clear cell renal cell carcinoma patients

Advances in Anti-Tumor Treatments Targeting the CD47/SIRPα Axis

EGFR‐Induced and c‐Src‐Mediated CD47 Phosphorylation Inhibits TRIM21‐Dependent Polyubiquitylation and Degradation of CD47 to Promote Tumor Immune Evasion

Evaluation of CD47 in the Suppressive Tumor Microenvironment and Immunotherapy in Prostate Cancer

Abstract 1331: Targeting CD47 Triggers Macrophage-Dependent Brain Tumor Destruction in a Clinical Relevant Model

CD47 Blockade Inhibits Tumor Progression Through Promoting Phagocytosis of Tumor Cells by M2 Polarized Macrophages in Endometrial Cancer

CD47 deficiency in tumor stroma promotes tumor progression by enhancing angiogenesis.

Role of CD47 in tumor immunity: a potential target for combination therapy

The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors

Microglia are effector cells of CD47-SIRPα antiphagocytic axis disruption against glioblastoma

Multiomics integration-based immunological characterizations of adamantinomatous craniopharyngioma in relation to keratinization

CD47 promotes ovarian cancer progression by inhibiting macrophage phagocytosis.

The Physiological and Therapeutic Role of CD47 in Macrophage Function and Cancer